Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.65 |
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.52 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804170 | 0.78 | DYRK1A (0.66) | DYRK1AIRAK4MAPK10DYRK3DYRK2 | |
| SCHEMBL182990 | 0.78 | DYRK1A (0.66) | DYRK1AIRAK4MAPK10CDK2MAPK8 | |
| SCHEMBL5094082 | 0.78 | MAPK8 (0.50) | MAPK10CDK2MAPK8MAPK9 | |
| SCHEMBL27584973 | 0.77 | CDK2 (0.67) | CDK2 | |
| SCHEMBL21208267 | 0.76 | DYRK1A (0.52) | DYRK1AIRAK4MAPK10CDK2MAPK8 | |
| SCHEMBL3548686 | 0.76 | DYRK1A (0.62) | DYRK1AIRAK4MAPK10DYRK2CDK2 | |
| SCHEMBL183868 | 0.74 | MAPK9 (0.54) | DYRK1ADYRK3DYRK2CDK2MAPK9 | |
| SCHEMBL17943211 | 0.73 | CDK2 (0.77) | DYRK1AIRAK4MAPK10CDK2MAPK8 | |
| SCHEMBL12272986 | 0.73 | CSNK1E (0.58) | DYRK1ADYRK3DYRK2CDK2CCNA2 | |
| SCHEMBL412757 | 0.73 | MAPK14 (0.49) | CDK2CCNA2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| CN-100415744-C | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7345050-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | disclosed |
| US-7345050-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| CN-1823064-A | 2-arylamino-pyrimidines for the treatment of GSK 3-related disorders | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | CN | disclosed |
| CN-1174981-C | Imidazo [1, 2-A ] pyridine and pyrazolo [2, 3-A ] pyridine derivatives | — | 2004-11-10 | — | — | CN | disclosed |
| US-20040077642-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | DYRK1A 483/4885IRAK4 720/4885MAPK10 568/4885 |
| US-20040077642-A1 | Pyrimidine compounds | TYMP, DPYD, TYMS | DYRK1A 3773/4885IRAK4 2970/4885MAPK10 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.